Moderna’s Covid-19 vaccine is currently licensed for people aged 18 and over.
Last month, Moderna published the results of a Phase 2/3 trial involving 3,732 children aged 12 to 17 in the United States; blood tests showed the vaccine produced an immune response equivalent to previous findings in adults. In this trial, initial observations revealed that none of the children who received the vaccine fell ill with Covid-19 from 14 days after their second dose. Four of the children who received the placebo tested positive for Covid-19.
The company has already applied for a vaccine authorization for younger people with regulatory agencies in Canada and Europe.
Pfizer received clearance for people as young as 12 to use its coronavirus vaccine on May 10.
The other Covid-19 vaccine available in the United States, manufactured by Johnson & Johnson, is currently licensed for people aged 18 and over.